Search hospitals > California > Davis
Sutter Davis Hospital
Claim this profileDavis, California 95616
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Relapse
Conducts research for Stomach Cancer
96 reported clinical trials
7 medical researchers
Summary
Sutter Davis Hospital is a medical facility located in Davis, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Sutter Davis Hospital is involved with conducting 96 clinical trials across 254 conditions. There are 7 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Jorge A. Garcia-Young.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus8 years of reported clinical research
Expert in Thyroid Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
68 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
50 drugs studied
Kristie A. BobolisSutter Medical Center Sacramento1 year of reported clinical research
Studies Breast Cancer
Studies Breast cancer
9 reported clinical trials
24 drugs studied
Jorge A. Garcia-YoungSutter Solano Medical Center/Cancer Center9 years of reported clinical research
Studies Skin Cancer
Studies Cutaneous Melanoma
7 reported clinical trials
20 drugs studied
Clinical Trials running at Sutter Davis Hospital
Breast Cancer
Lung Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Breast cancer
Skin Cancer
Multiple Myeloma
Esophageal cancer
Stomach Cancer
Esophageal Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Sutter Davis Hospital?
Sutter Davis Hospital is a medical facility located in Davis, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Relapse, Stomach Cancer and other specialties. Sutter Davis Hospital is involved with conducting 96 clinical trials across 254 conditions. There are 7 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Jorge A. Garcia-Young.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.